We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
To save content items to your account,
please confirm that you agree to abide by our usage policies.
If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account.
Find out more about saving content to .
To save content items to your Kindle, first ensure no-reply@cambridge.org
is added to your Approved Personal Document E-mail List under your Personal Document Settings
on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part
of your Kindle email address below.
Find out more about saving to your Kindle.
Note you can select to save to either the @free.kindle.com or @kindle.com variations.
‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi.
‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.
Considering the crystallographic data of the Human HMG-CoA reductase (HMGR) complexed with statins, a quantum chemistry study, based on the density functional theory, is performed to estimate the interaction energy for each statin, when one considers binding pockets of different sizes, based solely on the interpretation of crystallographic data of the HMGR–statin complex. Assuming a correlation between the statin potency and the strength of the HMGR–statin binding energies, clinical data of these cholesterol-lowering drugs are successfully explained after stabilization of the calculated binding energy for a larger size of the ligand-interacting HMGR region. The statins atorvastatin and rosuvastatin are shown to be the most strongly bound HMGR inhibitors, while simvastatin and fluvastatin are the weakest ones. An accurate description of the residue–ligand interaction energies at the binding site suggests a quantum chemistry–based route for the development of new statin derivatives.
Recommend this
Email your librarian or administrator to recommend adding this to your organisation's collection.